Na Cocer Peptides rayt 
am 15 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Minin
Prostamax na wan tin we gɛt fɔ du wit bayɔaktiv pεptida dɛm we dɔn sho se i ebul fɔ trit krεse nɔr baktriyal prɔstataytis ɛn ɔda kכndishכn dεm. Prostamax na fכmyuleshכn we riliyt to bayoaktiv pεptida dεm. di bayomodulatכri pεpti dεm de ple imכtant rol insay di bכdi, we de rεgεl difrεn fysiolojikal prכsεs dεm lεk di sεl dεm we de gro, difrεns, mεtabolism, εn di imyun rεspכns dεm. as wan pan dεn kayn tin dεm ya, Prostamax de sho spεsifi k tכgεt prכpati dεm, patikyuכl we de sho wan mak afiniti fכ di prכstat tisu, εn dat mek dεn kכl am as prכstatotropik ejen.
frכm in klasification, i difrεn frכm tradishכnal prכstat-tכgεt ejen dεm we kכmכt frכm plant εkstrakt (lεk saw palmetto εkstrakt) כ animal prכstat εkstrakt. pan ɔl we dɛn dɔn yuz dɛn tradishɔnal fɔmyulashɔn ya fɔ trit kɔndishɔn dɛn lɛk kronik nɔ-bakterial prɔstataytis, Prostamax, wit in yon peptide strɔkchɔ, de gi nyu we fɔ trit sik dɛn we gɛt fɔ du wit prɔstat.
Di we aw dɛn de du am
di ifekt dεm pan di inflammatory prכsεs insay krεse nכnbakterial prכstataytis: Insay di patכlayz invayroment fכ krεse nכnbakterial prכstataytis, di prכstat tisu de gεt siriכs inflammatory riakshכn dεm, we inklud swεla, vaskulכr kכnjεshכn, εn limfoyd infiltεshכn. Prostamax de wok fayn fayn wan fɔ mek dɛn sayn ya we de mek pɔsin fil bad. bay we i de rεgεl di εksprεshכn εn rilis fכ inflammatory cytokines, i de inhεbit di infiltεshכn εn aktibכshכn fכ inflammatory sεl dεm, we de ridyus di intensiti fכ di inflammatory rεspכns. i kin rεgεl bak di prodyushכn fכ di kεmokin dεm, we de ridyus di kεmotaktik agregεshכn fכ di inflammatory sεl dεm to di prכstat tisu, we de dכn di siriכs inflameshn. fכ inflameshn-induced tisu dεm we de pwεl, Prostamax kin promuot di sεl rεpa εn rigεnεreshכn mεkanism dεm fכ mεnten di nכmal strכkchכ εn fכnshכn fכ di prכstat tisu, we de mek di fibrosis εn atrofi nכ go bifo.
ifekt dεm pan kromatin strכkchכ: na di sεlyul mכlikul lεvεl, Prostamax gεt sכm impak pan di hכman limfosayt kromatin. di kromatin insay hכman limfosayt dεm de go tru tu dεnaturashכn stεp dεm we kכrεspכnd to difrεn tεmprachכ εn hεt chenj dεm. Prostamax de indyuz tεmral ridistribushכn, we de shift di tu absכpshכn pik dεm to lכw tεmprachכ, wit T_d(VII) we de dכn bay 2.9°C εn T_d(VIII) de dכn bay 1.0°C. dis fεnomen de sho se Prostamax kin altεr kromatin strכkchכ, we kin riliyt to di rilaks fכ 30 nm tik fayv dεm insay 10 nm tik fayv dεm. dis kayn ajɔstmεnt dεm na di kromatin strכkchכ de infכlכw di jin εksprεshכn εn rεguleshכn mכr, we de mek i gεt indaykt impak pan sεlyul fysiolojikal fכnshכn dεm.
Ifɛkt dɛn
Fɔ mek di inflamɛns nɔ bɔku pan di prɔstataytis we nɔ gɛt baktriyal: Krɔnik prɔstataytis we nɔ gɛt baktri na wan pan di tin dɛn we kin apin to pɔsin we gɛt yurolɔjik, ɛn tradishɔnal drɔg tritmɛnt dɛn kin gi rizɔlt we nɔ satisfay, wit ay rit we kin kam bak afta dɛn dɔn trit am. Insay ɛkspirimɛnt stɔdi, Prostamax sho fayn fayn anti-inflammatory ifɛkt dɛm, i ifɛktiv wan ridyus di sayn dɛm fɔ krɛse inflameshɔn, i de mek di prɔstat tisu swel, i ridyus di vaskyuɛl kɔnjɛshɔn, ɛn i de stɔp di limfoyd infiltrɛshɔn. Dis na impɔtant tin fɔ mek di sik pipul dɛn gɛt bɛtɛ sik ɛn fɔ mek dɛn kwaliti layf bɛtɛ. We i de ridyus inflamɛns, i kin mek di sik pipul dɛn nɔ fil fayn lɛk pen ɛn urinary abnormalities, we de gi nyu ifektiv tritmɛnt opshɔn fɔ kronik nɔ-bakterial prɔstataytis.
fכ mek di prכstat tisu dכn at εn atrofi: כnda di lכng stimulashכn fכ krεse inflameshn, di prכstat tisu kin protεn fכ patכlayz chenj dεm lεk fכ harden εn atrofi, we de mek di prכstat in nכmal fכnshכn mכr. Prostamax kin akt fכ mek dεn advεs patכlayz prכsεs dεm ya nכ go bifo. i de ajɔst dis bay we i de rεgεl di mεtabolik bεlε na di εkstra sεlyul matris, i de inhεbit di fכs fכ proliferashכn fכ di fayv tisu dεm, εn dat de mek di prכstat tisu dεm nכ de at. bay we i de mek di sεl dεm sכvayv εn di proliferashכn signal path dεm, i de mεnten di nכmba εn fכnshכn fכ di prכstat sεl dεm, we de mek di tisu dεm nכ atrofi. dis na imכtant fכ mεnten di nכmal fysiolojikal strכkchכ εn fכnshכn fכ di prכstat εn fכ slo di sik prכgreshכn.
εnhans animal sεks fכnshכn: Insay rilevεnt εkspεriεns, dεn fכnshכn se Prostamax kin εnhans animal sεks fכnshכn. i de infכlכw di haypothalamic-pituitary-gonadal aks, i de rεgεl di sekreshכn εn rilis fכ sεks כmon dεm, we de afekt animal sεks fכnshכn fayn fayn wan. Dis ifekt de sho se Prostamax kin gɛt aplikeshɔn valyu na di fild fɔ riprodaktiv wɛlbɔdi, nɔto jɔs fɔ pasɛnt dɛn we gɛt prɔstataytis bɔt fɔ ɔda pipul dɛn we dɛn afɛkt wit sɛkshɔnal disfɔkshɔn, we kin mek dɛn gi nyu tritmɛnt opshɔn dɛn.
Pכtεnshal ifekt dεm pan di kromatin strכkchכ-rεlatεd fכnshכn dεm: biכs Prostamax kin indyuz tεmכl ridistribushכn εn strכkchכral chenj dεm na di limfosayt kromatin, pan כl we in kכmprεhεnsiv ifekt dεm pan כvala fysiolojikal fכnshכn dεm nכ yet fכ elucidate, tiori, dεn kayn chenj dεm ya na kromatin strכkchכ kin infכlכw jin transkripshכn εn εksprεshכn, we de afekt sεlyul difrεns, proliferashכn, εn di imyun rεguleshכn fכnshכn dεm. i kin indyεkt infכmeshכn di bכdi in imyun rεspכns bay we i de rεgεl di εksprεshכn fכ sכm kכl jin dεm, we de afekt di aktiviti εn fכnshכn fכ di imyun sεl dεm.
Aplikeshɔn dɛn
Tritmɛnt fɔ kronik nɔ-bakterial prɔstataytis: Gi Prostamax in ɛfifikɛshɔn fɔ stɔp inflamɛns, fɔ mek di tisu fibrosis, ɛn atrofi fɔ kronik nɔ-bakterial prɔstataytis, i gɛt prɔmis pɔtnɛshɛl fɔ aplikeshɔn insay di tritmɛnt fɔ dis kɔndishɔn.
Pɔtɛnɛshɛl aplikeshɔn dɛn na riprodaktiv wɛlbɔdi: Bikɔs Prostamax kin ɛp fɔ mek animal dɛn du mami ɛn dadi biznɛs, dis kwaliti de gi am pɔtɛnɛshɛl aplikeshɔn valyu na di fild fɔ riprodaktiv wɛlbɔdi. Fɔ di sik pipul dɛn we gɛt prɔblɛm wit fεtiliti we dɛn kin kɔz bikɔs dɛn nɔ kin ebul fɔ du mami ɛn dadi biznɛs ɔ di wan dɛn we kin gɛt prɔblɛm wit di we aw dɛn de du mami ɛn dadi biznɛs bikɔs dɛn ol, Prostamax kin kɔmɔt as nyu tritmɛnt opshɔn.
Risach tul insay sεl bayoloji εn mכlikul bayoloji: di yכŋ ifekt we Prostamax de gi pan limfosayt kromatin strכkchכ de mek i bi pכtεnshal tul insay sεl bayoloji εn mכlikul bayoloji risach. di risach dεm kin yuz am fכ stכdi di rilayshכn bitwin kromatin strכkchכ εn jin εksprεshכn rεguleshכn, εn fכ εksplכr di mכlikul mεkanism dεm we de כndalayn fysiolojikal prכsεs dεm lεk sεl difrεns, proliferashכn, εn imyun rεguleshכn. bay we dεn trit sεl dεm wit Prostamax, risecharch dεm kin obsכv dinamik chenj dεm na di kromatin strכkchכ εn asosiet כltεrayshכn dεm na di jin εksprεshכn, we de mek dεn gεt dip insayt dεm insay di kכmpleks intasεlulyar signal nεtwכk dεm. i kin bi bak as tul fכ skrεn εn fכ no nyu jin dεm εn signal path dεm we riliyt to kromatin strכkchכ rεguleshכn, fכ gi nyu pεspεktiv εn mεtכd fכ layf sayns risεch.
Dɔn
fכ sכmari, Prostamax, as sכbstans we rilet to bayoaktiv pεptida dεm, de sho mכlti fכs advantej dεm fכ trit krεse nכnbakterial prכstataytis, inklud fכ ridyus inflameshn, fכ mek di tisu fכ fכm fכ fכm εn atrofi, εn fכ εnhans animal sεks fכnshכn. di we aw i de wok involv fכ rεgεl di inflammatory prכsεs dεm, fכ chenj di kromatin strכkchכ, εn כda aspek dεm. We i kam pan aw fɔ yuz am, i nɔ jɔs gɛt prɔmis fɔ trit kronik nɔ-bakterial prɔstataytis bɔt i gɛt valyu bak pan di fild dɛn fɔ riprodaktiv wɛlbɔdi, ɛn bak pan sɛlular ɛn mɔlikul bayoloji risach.
Sos dɛn we dɛn pul
[1] Borovskaya T. G., Pakhomova A. V., Vychuzhanina A. V., ɛn ɔda pipul dɛn. Ekspirimental stכdi כf di drog efyushכn Prostamax in di tεrapi fכ krכnik aseptik prכstataytis εn in komplikεshכn dεm[J]. Modan Risach in Inflameshɔn, 2013,Vol.02No.03:5.DOI:10.4236/mri.2013.23007.
[2] Meskhi T, Khachidze D, Barbakadze S, ɛn ɔda pipul dɛn. [di inflכεns fכ di pεptida bayכrεgεlεt prostamaks pan hεterokromatin fכ hכman limfosayt dεm in situ][J]. Biofizika, 2004,49(6):1091-1093.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Ritriv&db=pubmed&dopt=Abstrakt&list_uids=15612551&kwɛri_hl=1
Prodak we de fɔ yuz fɔ risach nɔmɔ:
